Citations 261

Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation

The Oncologist | August 24, 2004 | Volume: 8 | Issue: 5 | Pages: 474-487

10.1634/theoncologist.8-5-474 | PMID 14530501

AbstractLearning ObjectivesAfter completing this course, the reader will be able to:Explain the side effects of hormonal ablation therapy for prostate cancer. Provide a list of potential non-hormonal therapies for treatment of vasomotor symptoms. Appreciate the impact of hormonal ablation therapy on bone mineral density.Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.comAndropause, or the age-related decline in serum testosterone, has become a popular topic in the medical literature over the past several years. Andropause includes a constellation of symptoms related to lack of androgens, including diminished libido, decreased generalized feeling of well-being, osteoporosis, and a host of other symptoms. The andropause syndrome is very prominent in men undergoing hormonal ablation therapy for prostate cancer. Most significant in this population are the side effects of hot flashes, anemia, gynecomastia, depression, cognitive decline, sarcopenia, a decreased overall quality of life, sexual dysfunction, and osteoporosis with subsequent bone fractures. The concept of andropause in prostate cancer patients is poorly represented in the literature. In this article, we review the current literature on the symptoms, signs, and possible therapies available to men who cannot take replacement testosterone.